Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLTNASDAQ:COCPNASDAQ:ICCCNASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.38-6.4%$0.42$0.30▼$10.62$54.34M23.36 million shs1.56 million shsCOCPCocrystal Pharma$1.42-2.7%$1.43$1.12▼$3.26$14.44M2.1327,907 shs9,074 shsICCCImmuCell$6.25-4.1%$5.33$3.34▼$6.84$56.48M0.2322,061 shs21,660 shsSKYESkye Bioscience$2.20+15.8%$1.96$1.14▼$12.45$68.15M1.74366,207 shs267,300 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-6.37%-11.87%-3.74%-26.33%-90.59%COCPCocrystal Pharma-2.74%-6.27%-16.91%-18.39%-35.45%ICCCImmuCell-4.14%+12.82%+13.64%+14.05%+37.67%SKYESkye Bioscience+15.79%+11.68%+20.88%-20.86%-81.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics3.9201 of 5 stars3.32.00.04.72.12.50.6COCPCocrystal Pharma3.1317 of 5 stars3.55.00.00.02.81.70.6ICCCImmuCell0.3118 of 5 stars0.03.00.00.03.10.00.0SKYESkye Bioscience1.0648 of 5 stars3.51.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,489.37% UpsideCOCPCocrystal Pharma 3.00Buy$7.00392.96% UpsideICCCImmuCell 0.00N/AN/AN/ASKYESkye Bioscience 3.00Buy$16.60654.55% UpsideCurrent Analyst Ratings BreakdownLatest COCP, ICCC, SKYE, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/14/2025APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.503/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$265K205.04N/AN/A($0.20) per share-1.92COCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/AICCCImmuCell$27.30M2.07N/AN/A$3.23 per share1.93SKYESkye BioscienceN/AN/AN/AN/A($0.17) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$0.43N/AN/AN/AN/A-260.75%-76.04%8/6/2025 (Estimated)COCPCocrystal Pharma-$17.98M-$1.57N/AN/AN/AN/A-94.62%-78.24%8/13/2025 (Estimated)ICCCImmuCell-$5.78M-$0.07N/A∞N/A-15.99%-15.32%-8.81%8/11/2025 (Estimated)SKYESkye Bioscience-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/ALatest COCP, ICCC, SKYE, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/14/2025Q1 2025ICCCImmuCellN/A$0.16N/A$0.16N/A$8.07 million5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/A3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.061.06COCPCocrystal PharmaN/A7.327.32ICCCImmuCell0.363.111.44SKYESkye BioscienceN/A14.1914.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%COCPCocrystal Pharma6.72%ICCCImmuCell13.47%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics8.60%COCPCocrystal Pharma28.14%ICCCImmuCell6.60%SKYESkye Bioscience4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30141.58 million106.35 millionOptionableCOCPCocrystal Pharma1010.17 million7.57 millionNot OptionableICCCImmuCell709.04 million8.32 millionNot OptionableSKYESkye Bioscience1130.98 million29.43 millionOptionableCOCP, ICCC, SKYE, and APLT HeadlinesRecent News About These CompaniesLeo Miller: Page 6May 25 at 9:23 AM | entrepreneur.com3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesMay 23, 2025 | zacks.comSkye Bioscience to Participate in Upcoming Investment ConferencesMay 22, 2025 | globenewswire.comSkye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity TreatmentMay 21, 2025 | nasdaq.comQ&A: Next wave of obesity drugs may ‘afford a lot of advantages’May 20, 2025 | healio.comArecor shares climb 18% on collaboration with Skye BioscienceMay 19, 2025 | lse.co.ukArecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate NimacimabMay 19, 2025 | cambridgenetwork.co.ukSkye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | finanznachrichten.deArecor enters formulation partnership with Skye BioscienceMay 19, 2025 | sharecast.comArecor shares jump 10% on obesity drug partnership with Skye BioscienceMay 19, 2025 | proactiveinvestors.co.ukArecor partners with Skye Bioscience to improve formulation of obesity drugMay 19, 2025 | proactiveinvestors.co.ukSkye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | globenewswire.comEnsign Peak Advisors Inc Sells 132,713 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE)May 18, 2025 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of "Buy" from AnalystsMay 16, 2025 | marketbeat.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 13, 2025 | globenewswire.comSkye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on ObesityMay 13, 2025 | globenewswire.comZepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...May 12, 2025 | medpagetoday.comSkye Bioscience (NASDAQ:SKYE) Issues Quarterly Earnings ResultsMay 12, 2025 | marketbeat.comEarnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D ExpansionMay 10, 2025 | investing.comSkye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSkye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in ObesityMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, ICCC, SKYE, and APLT Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.38 -0.03 (-6.37%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.39 +0.00 (+1.09%) As of 05/27/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Cocrystal Pharma NASDAQ:COCP$1.44 -0.02 (-1.71%) As of 05/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.ImmuCell NASDAQ:ICCC$6.25 -0.27 (-4.14%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$6.18 -0.07 (-1.04%) As of 05/27/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Skye Bioscience NASDAQ:SKYE$2.20 +0.30 (+15.79%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.16 -0.04 (-1.82%) As of 05/27/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
